Case of Anthrax abdominal form in Kazakhstan
Anthrax is a dangerous zoonotic infection that is transmitted from farm animals to humans, when cutting, butchering infected animals, contact with meat and other animal products. Infection occurs by contact, alimentary, aerogenic pathways, while developing corresponding clinical forms – skin /ulcerative, abdominal / intestinal, pulmonary /pneumonic
Impact of Anesthetics on the ST segment among Patients with Brugada syndrome: Case Series.
1.1. Aim: Brugada syndrome is a canalopathy causing rhythmic sudden death. The use of many drugs such as anesthetics but also many analgesics are contraindicated or not recommended in this pathology. The literature shows a low-level evidence while clinical experience may bring additional knowledge.
Cytokine storm syndrome in COVID-19 patients: Characteristics and Diagnosis
Cytokine storm syndrome (CSS) is a critical condition induced by a cascade of cytokine activation, characterized by overwhelming systemic inflammation, hyperferritinaemia, haemodynamic instability and multiple organ failure. At the end of 2019, the disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in Wuhan, China, and rapidly developed into a global pandemic. There is a dramatic increase of inflammatory cytokines in patients with COVID-19, suggesting the existence of cytokine storm in some critical illness patients. Here, we summarize the pathogenesis, clinical manifestation of CSS, and highlight the current understanding about the recognition and diagnosis of CSS in COVID-19.
Multiple-scale Computational Studies of Redox-controlled Supramolecular Co-assembly Nanoplatform: Toward Immunochemotherapy-driven Antitumor Augment
Programmed cell death protein 1 (PD1)/programmed death ligand 1 (PD-L1) blockades provide an effective and safe therapeutic option in the field of refractory cancer therapy. However, not more than 30% response rate of most cancers seriously impedes their therapeutic efficacy. Previous investigations have proved the effectiveness of combining chemotherapy with immunotherapy for unsatisfactory response to anti-PD1